CA1327358C
(fr)
|
1987-11-17 |
1994-03-01 |
Morio Fujiu |
Derives fluorocytidine
|
WO1989006692A1
(fr)
*
|
1988-01-12 |
1989-07-27 |
Genentech, Inc. |
Procede de traitement de cellules tumorales par inhibition de la fonction receptrice du facteur de croissance
|
CA2045231A1
(fr)
*
|
1990-07-19 |
1992-01-20 |
Victor Ling |
Glycoproteine de membrane cellulaire ayant une resistance aux agents antineoplasiques contenant du platine
|
ES2206447T3
(es)
|
1991-06-14 |
2004-05-16 |
Genentech, Inc. |
Anticuerpo humanizado para heregulina.
|
TW254946B
(fr)
|
1992-12-18 |
1995-08-21 |
Hoffmann La Roche |
|
AU671491B2
(en)
|
1992-12-18 |
1996-08-29 |
F. Hoffmann-La Roche Ag |
N-oxycarbonyl substituted 5'-deoxy-5-fluorcytidines
|
US5362718A
(en)
|
1994-04-18 |
1994-11-08 |
American Home Products Corporation |
Rapamycin hydroxyesters
|
NZ272608A
(en)
|
1994-07-22 |
2000-05-26 |
Lilly Co Eli |
Inhibiting bone loss by administering a bisphosphonate and a second compound selected from various compounds, including 2-phenyl-3-aroylbenzothienes; bisphosphonate combination salts
|
US5476932A
(en)
|
1994-08-26 |
1995-12-19 |
Hoffmann-La Roche Inc. |
Process for producing N4-acyl-5'-deoxy-5-fluorocytidine derivatives
|
GB9508565D0
(en)
|
1995-04-27 |
1995-06-14 |
Zeneca Ltd |
Quiazoline derivative
|
GB9508538D0
(en)
|
1995-04-27 |
1995-06-14 |
Zeneca Ltd |
Quinazoline derivatives
|
US6267958B1
(en)
*
|
1995-07-27 |
2001-07-31 |
Genentech, Inc. |
Protein formulation
|
JP3437685B2
(ja)
*
|
1995-09-12 |
2003-08-18 |
株式会社東芝 |
交直変換装置の制御保護システム
|
WO1997017329A1
(fr)
|
1995-11-07 |
1997-05-15 |
Kirin Beer Kabushiki Kaisha |
Derives de quinoline et derives de quinazoline inhibant l'autophosphorylation d'un recepteur de facteur de croissance originaire de plaquettes, et compositions pharmaceutiques les contenant
|
US5760041A
(en)
|
1996-02-05 |
1998-06-02 |
American Cyanamid Company |
4-aminoquinazoline EGFR Inhibitors
|
UA73073C2
(uk)
|
1997-04-03 |
2005-06-15 |
Уайт Холдінгз Корпорейшн |
Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція
|
US6002008A
(en)
*
|
1997-04-03 |
1999-12-14 |
American Cyanamid Company |
Substituted 3-cyano quinolines
|
US6426383B1
(en)
*
|
1997-05-28 |
2002-07-30 |
Nalco Chemical Company |
Preparation of water soluble polymer dispersions from vinylamide monomers
|
US6251912B1
(en)
|
1997-08-01 |
2001-06-26 |
American Cyanamid Company |
Substituted quinazoline derivatives
|
SE9704545D0
(sv)
*
|
1997-12-05 |
1997-12-05 |
Astra Pharma Prod |
Novel compounds
|
BR9914167B1
(pt)
|
1998-09-29 |
2011-03-09 |
|
compostos e composições farmacêuticas compreendendo 3-ciano quinolinas substituìdas.
|
US6297258B1
(en)
*
|
1998-09-29 |
2001-10-02 |
American Cyanamid Company |
Substituted 3-cyanoquinolines
|
US6288082B1
(en)
*
|
1998-09-29 |
2001-09-11 |
American Cyanamid Company |
Substituted 3-cyanoquinolines
|
US6432979B1
(en)
*
|
1999-08-12 |
2002-08-13 |
American Cyanamid Company |
Method of treating or inhibiting colonic polyps and colorectal cancer
|
US6277983B1
(en)
*
|
2000-09-27 |
2001-08-21 |
American Home Products Corporation |
Regioselective synthesis of rapamycin derivatives
|
TWI256395B
(en)
|
1999-09-29 |
2006-06-11 |
Wyeth Corp |
Regioselective synthesis of rapamycin derivatives
|
WO2001051919A2
(fr)
|
2000-01-07 |
2001-07-19 |
Transform Pharmaceuticals, Inc. |
Formation, identification et analyse a productivites elevees de formes solides diverses
|
US6384051B1
(en)
|
2000-03-13 |
2002-05-07 |
American Cyanamid Company |
Method of treating or inhibiting colonic polyps
|
TWI310684B
(en)
*
|
2000-03-27 |
2009-06-11 |
Bristol Myers Squibb Co |
Synergistic pharmaceutical kits for treating cancer
|
GB0008368D0
(en)
*
|
2000-04-06 |
2000-05-24 |
Astrazeneca Ab |
Combination product
|
US7306801B2
(en)
*
|
2000-05-15 |
2007-12-11 |
Health Research, Inc. |
Methods of therapy for cancers characterized by overexpression of the HER2 receptor protein
|
AU2001283139A1
(en)
*
|
2000-08-11 |
2002-02-25 |
Wyeth |
Method of treating estrogen receptor positive carcinoma
|
TWI286074B
(en)
*
|
2000-11-15 |
2007-09-01 |
Wyeth Corp |
Pharmaceutical composition containing CCI-779 as an antineoplastic agent
|
AR042586A1
(es)
*
|
2001-02-15 |
2005-06-29 |
Sugen Inc |
3-(4-amidopirrol-2-ilmetiliden)-2-indolinona como inhibidores de la protein quinasa; sus composiciones farmaceuticas; un metodo para la modulacion de la actividad catalitica de la proteinquinasa; un metodo para tratar o prevenir una afeccion relacionada con la proteinquinasa
|
SG152906A1
(en)
|
2001-04-06 |
2009-06-29 |
Wyeth Corp |
Antineoplastic combinations such as rapamycin together with gemcitabine or fluorouracil
|
TWI296196B
(en)
*
|
2001-04-06 |
2008-05-01 |
Wyeth Corp |
Antineoplastic combinations
|
TWI233359B
(en)
*
|
2001-04-06 |
2005-06-01 |
Wyeth Corp |
Pharmaceutical composition for treating neoplasm
|
SG153647A1
(en)
|
2001-06-01 |
2009-07-29 |
Wyeth Corp |
Antineoplastic combinations
|
US20020198137A1
(en)
*
|
2001-06-01 |
2002-12-26 |
Wyeth |
Antineoplastic combinations
|
WO2002102976A2
(fr)
|
2001-06-14 |
2002-12-27 |
The Regents Of The University Of California |
Mutations dans la tyrosine kinase bcr-abl associees a la resistance a sti-571
|
UA77200C2
(en)
*
|
2001-08-07 |
2006-11-15 |
Wyeth Corp |
Antineoplastic combination of cci-779 and bkb-569
|
PL370137A1
(en)
|
2001-11-27 |
2005-05-16 |
Wyeth Holdings Corporation |
3-cyanoquinolines as inhibitors of egf-r and her2 kinases
|
AU2003210787B2
(en)
*
|
2002-02-01 |
2009-04-23 |
Medinol Ltd. |
Phosphorus-containing compounds & uses thereof
|
TWI275390B
(en)
|
2002-04-30 |
2007-03-11 |
Wyeth Corp |
Process for the preparation of 7-substituted-3- quinolinecarbonitriles
|
AU2003247483A1
(en)
*
|
2002-05-30 |
2003-12-31 |
The Children's Hospital Of Philadelphia |
Methods for treatment of acute lymphocytic leukemia
|
AU2003238871B2
(en)
*
|
2002-06-05 |
2009-04-23 |
Cedars-Sinai Medical Center |
Method of treating cancer using kinase inhibitors
|
AU2003248813A1
(en)
*
|
2002-07-05 |
2004-01-23 |
Beth Israel Deaconess Medical Center |
Combination of mtor inhibitor and a tyrosine kinase inhibitor for the treatment of neoplasms
|
WO2004010937A2
(fr)
*
|
2002-07-26 |
2004-02-05 |
Advanced Research & Technology Institute At Indiana University |
Methode de traitement du cancer
|
US20040096436A1
(en)
*
|
2002-08-02 |
2004-05-20 |
Regents Of The University Of California |
Methods for inhibiting protein kinases in cancer cells
|
US20040209930A1
(en)
*
|
2002-10-02 |
2004-10-21 |
Carboni Joan M. |
Synergistic methods and compositions for treating cancer
|
CL2004000016A1
(es)
|
2003-01-21 |
2005-04-15 |
Wyeth Corp |
Compuesto derivado de cloruro de 4-amino-2-butenoilo o una sal farmaceuticamente aceptable del mismo; procedimiento para preparar dicho compuesto, util como intermediario en la sintesis de compuestos inhibidores de proteina quinasa tirosina.
|
KR20050122199A
(ko)
*
|
2003-01-23 |
2005-12-28 |
티.케이. 시그널 리미티드 |
표피성장인자 수용체 티로신 키나제의 비가역성 억제제 및 그의 용도
|
CN1437942A
(zh)
|
2003-02-08 |
2003-08-27 |
杭州华卫制药技术开发有限公司 |
注射用长春瑞滨粉针剂及制备方法
|
UA83484C2
(uk)
*
|
2003-03-05 |
2008-07-25 |
Уайт |
Спосіб лікування раку грудей комбінацією похідного рапаміцину і інгібітора ароматази - летрозолу, фармацевтична композиція
|
MXPA05010582A
(es)
*
|
2003-04-22 |
2005-11-23 |
Wyeth Corp |
Combinaciones antineoplasicas.
|
US20050043233A1
(en)
|
2003-04-29 |
2005-02-24 |
Boehringer Ingelheim International Gmbh |
Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
|
UA84156C2
(ru)
|
2003-07-23 |
2008-09-25 |
Байер Фармасьютикалс Корпорейшн |
Фторозамещённая омега-карбоксиарилдифенилмочевина для лечения и профилактики болезней и состояний
|
US20050025825A1
(en)
|
2003-07-31 |
2005-02-03 |
Xanodyne Pharmacal, Inc. |
Tranexamic acid formulations with reduced adverse effects
|
MXPA06001110A
(es)
|
2003-08-01 |
2006-04-11 |
Wyeth Corp |
Uso de una combinacion de un inhibidor de la cinasa del receptor del factor de crecimiento epidermico y agentes citotoxicos para el tratamiento e inhibicion del cancer.
|
KR20060066733A
(ko)
|
2003-08-19 |
2006-06-16 |
와이어쓰 홀딩스 코포레이션 |
4-아미노-3-퀴놀린카보니트릴의 제조방법
|
WO2005034955A1
(fr)
|
2003-09-15 |
2005-04-21 |
Wyeth |
Utilisation de quinolines substituees comme inhibiteurs de la tyrosine kinase
|
US7399865B2
(en)
*
|
2003-09-15 |
2008-07-15 |
Wyeth |
Protein tyrosine kinase enzyme inhibitors
|
TWI372066B
(en)
|
2003-10-01 |
2012-09-11 |
Wyeth Corp |
Pantoprazole multiparticulate formulations
|
US20050142192A1
(en)
|
2003-10-15 |
2005-06-30 |
Wyeth |
Oral administration of [2-(8,9-dioxo-2,6-diazabicyclo[5.2.0]non-1(7)-en-2-yl)alkyl] phosphonic acid and derivatives
|
WO2005049021A1
(fr)
|
2003-11-03 |
2005-06-02 |
Oy Helsinki Transplantation R & D Ltd |
Substances et procedes pour inhiber l'hyperplasie neointime
|
WO2005044091A2
(fr)
|
2003-11-05 |
2005-05-19 |
Board Of Regents, The University Of Texas System |
Methodes diagnostiques et therapeutiques et compositions impliquant des pten et le cancer du sein
|
TW200526684A
(en)
|
2003-11-21 |
2005-08-16 |
Schering Corp |
Anti-IGFR1 antibody therapeutic combinations
|
WO2005055943A2
(fr)
*
|
2003-12-04 |
2005-06-23 |
Amr Technology, Inc. |
Derives de la vinorelbine
|
US9016221B2
(en)
|
2004-02-17 |
2015-04-28 |
University Of Florida Research Foundation, Inc. |
Surface topographies for non-toxic bioadhesion control
|
AR047988A1
(es)
|
2004-03-11 |
2006-03-15 |
Wyeth Corp |
Combinaciones antineoplásicas de cci-779 y rituximab
|
KR101347613B1
(ko)
*
|
2004-03-31 |
2014-01-06 |
다나-파버 캔서 인스티튜트 인크. |
암에 걸린 인간 환자의 표피성장인자 수용체 표적 치료의 유효 가능성 결정 방법, 키트, 핵산 프로브 및 프라이머쌍
|
PT1748998E
(pt)
|
2004-05-28 |
2010-03-24 |
Hetero Drugs Ltd |
Novo processo de síntese estereoselectiva de sulfóxidos de benzimidazol
|
EP2592155B2
(fr)
*
|
2004-06-04 |
2019-09-11 |
Genentech, Inc. |
Mutations EGFR
|
WO2006008526A2
(fr)
|
2004-07-23 |
2006-01-26 |
Astrazeneca Ab |
Procede
|
US20060058311A1
(en)
|
2004-08-14 |
2006-03-16 |
Boehringer Ingelheim International Gmbh |
Combinations for the treatment of diseases involving cell proliferation
|
TW200616612A
(en)
|
2004-10-08 |
2006-06-01 |
Wyeth Corp |
Method for the teatment of polycystic kidney disease field of invention
|
WO2006044453A1
(fr)
|
2004-10-13 |
2006-04-27 |
Wyeth |
Analogues de la 17-hydroxywortmannine employés en tant qu’inhibiteurs de pi3k
|
US20080254497A1
(en)
|
2004-10-15 |
2008-10-16 |
Monogram Biosciences, Inc. |
Response Predictors for Erbb Pathway-Specific Drugs
|
US20060084666A1
(en)
*
|
2004-10-18 |
2006-04-20 |
Harari Paul M |
Combined treatment with radiation and an epidermal growth factor receptor kinase inhibitor
|
WO2006085168A2
(fr)
|
2005-01-07 |
2006-08-17 |
Ranbaxy Laboratories Limited |
Formes de dosage orales solides de ziprasidone
|
GB0501999D0
(en)
|
2005-02-01 |
2005-03-09 |
Sentinel Oncology Ltd |
Pharmaceutical compounds
|
DE602006021142D1
(de)
*
|
2005-02-03 |
2011-05-19 |
Gen Hospital Corp |
Verfahren zur behandlung von gefitinib-resistentem krebs
|
WO2006081985A1
(fr)
|
2005-02-04 |
2006-08-10 |
F. Hoffmann-La Roche Ag |
Traitement combine par un derive de n4-(oxycarbonyl substitue)-5'-desoxy-5-fluorocytidine et un inhibiteur de l'activite kinase du recepteur du facteur de croissance epidermique
|
MX2007009963A
(es)
|
2005-02-24 |
2007-09-26 |
Amgen Inc |
Mutaciones del receptor del factor de crecimiento epidermico.
|
PL1859793T3
(pl)
|
2005-02-28 |
2011-09-30 |
Eisai R&D Man Co Ltd |
Nowe połączone zastosowanie związku sulfonamidowego w leczeniu choroby nowotworowej
|
CA2610343A1
(fr)
|
2005-03-03 |
2006-09-08 |
Takeda Pharmaceutical Company Limited |
Composition a liberation controlee
|
CA2599445C
(fr)
|
2005-03-09 |
2022-05-03 |
Abbott Laboratories |
Procede diagnostique d'identification des patients candidats a un traitement au trastuzumab
|
GB0504994D0
(en)
|
2005-03-11 |
2005-04-20 |
Biotica Tech Ltd |
Novel compounds
|
US20060235006A1
(en)
|
2005-04-13 |
2006-10-19 |
Lee Francis Y |
Combinations, methods and compositions for treating cancer
|
CA2646257A1
(fr)
|
2005-04-14 |
2006-10-26 |
Wyeth |
Utilisation d'un inhibiteur kinase du recepteur du facteur de croissance epidermique (egfr) chez des patients resistant a la gefitinib
|
WO2006116016A2
(fr)
|
2005-04-21 |
2006-11-02 |
The Regents Of The University Of California |
Determinants moleculaires de la reponse de l'inhibiteur d'egfr kinase dans le glioblastome
|
DK1896034T3
(da)
|
2005-04-28 |
2010-05-17 |
Wyeth Corp |
Mikroniserede tanaproget-sammensætninger og fremgangsmåder til fremstilling af disse
|
WO2006120557A1
(fr)
|
2005-05-12 |
2006-11-16 |
Pfizer Inc. |
Polytherapie anticancereuse faisant intervenir du malate de sunitinib
|
JP2008542267A
(ja)
|
2005-05-25 |
2008-11-27 |
ワイス |
3−シアノ−キノリンと、それにより製造される中間体とを調製する方法
|
CN101203494A
(zh)
*
|
2005-05-25 |
2008-06-18 |
惠氏公司 |
合成经取代3-氰基喹啉和其中间物的方法
|
DE102005053679A1
(de)
|
2005-06-24 |
2006-12-28 |
Bayer Healthcare Ag |
Therapeutischer Einsatz von Moxifloxacin zur Rekonstruktion von Funktionsstörungen des Immunsystems
|
WO2007011619A2
(fr)
|
2005-07-15 |
2007-01-25 |
Wyeth |
Formes pharmaceutiques orales hautement biodisponibles a liberation retardee, de o-desmethylvenlafaxine succinate
|
US20100105031A1
(en)
|
2005-08-01 |
2010-04-29 |
Esai R & D Management Co., Ltd. |
Method for prediction of the efficacy of vascularization inhibitor
|
WO2007015578A1
(fr)
|
2005-08-02 |
2007-02-08 |
Eisai R & D Management Co., Ltd. |
Procédé d’analyse de l’effet d’un inhibiteur de vascularisation
|
EP1931798A1
(fr)
|
2005-10-05 |
2008-06-18 |
AstraZeneca UK Limited |
Méthode pour prédire ou surveiller la réponse d'un patient à un médicament de récepteur erbb
|
WO2007050495A2
(fr)
|
2005-10-26 |
2007-05-03 |
Children's Medical Center Corporation |
Methode permettant de pronostiquer une reponse a un anti-egfr
|
AR058505A1
(es)
*
|
2005-11-04 |
2008-02-06 |
Wyeth Corp |
Combinaciones antineoplasicas de temsirolimus y malato de sunitinib
|
CN103110948A
(zh)
|
2005-11-04 |
2013-05-22 |
惠氏公司 |
mTOR抑制剂、赫赛汀和/或HKI-272的抗肿瘤组合
|
SI1948180T1
(sl)
|
2005-11-11 |
2013-06-28 |
Boehringer Ingelheim International Gmbh |
Kombinacijsko zdravljenje raka, ki obsega EGFR/HER2 inhibitorje
|
PL1951274T3
(pl)
|
2005-11-24 |
2010-05-31 |
Aicuris Gmbh & Co Kg |
Parapoksywirusy w kombinacji z klasycznymi cytotoksycznymi środkami chemioterapeutycznymi jako biochemioterapia do leczenia raka
|
JP2007145745A
(ja)
|
2005-11-25 |
2007-06-14 |
Osaka Univ |
変異型EGFR下流シグナルを抑制するSrcファミリーチロシンキナーゼ阻害剤を含む肺癌治療剤およびその利用
|
EP1965770A2
(fr)
|
2005-12-22 |
2008-09-10 |
Wyeth a Corporation of the State of Delaware |
Formulations orales contenant de la tigecycline
|
WO2007095038A2
(fr)
|
2006-02-09 |
2007-08-23 |
Novartis Ag |
Mutations et polymorphismes du gène erbb2
|
CA2644841C
(fr)
|
2006-04-07 |
2013-07-16 |
Novartis Ag |
Utilisation d'inhibiteurs de c-src en combinaison avec un compose pyrimidylaminobenzamide pour traiter la leucemie
|
TW200806282A
(en)
|
2006-05-05 |
2008-02-01 |
Wyeth Corp |
Solid dosage formulations
|
IL282783B2
(en)
|
2006-05-18 |
2023-09-01 |
Caris Mpi Inc |
A system and method for determining a personalized medical intervention for a disease stage
|
TW200808728A
(en)
|
2006-05-23 |
2008-02-16 |
Wyeth Corp |
Method of preparing 4-halogenated quinoline intermediates
|
EP2032989B2
(fr)
|
2006-06-30 |
2015-10-28 |
Merck Sharp & Dohme Corp. |
Biomarqueur igfbp2
|
MX2009002710A
(es)
|
2006-09-18 |
2009-03-25 |
Boehringer Ingelheim Int |
Metodos para tratar canceres que portan mutaciones de egfr.
|
WO2008042216A2
(fr)
|
2006-09-28 |
2008-04-10 |
Follica, Inc. |
PROCÉDÉS, matÉriel et compositions pour gÉNÉrer de nouveaux follicules pileux et faire pousser les cheveux
|
WO2008043576A1
(fr)
|
2006-10-13 |
2008-04-17 |
Medigene Ag |
Utilisation de virus oncolytiques et d'agents anti-angiogéniques dans le traitement du cancer
|
MX2009006466A
(es)
|
2006-12-13 |
2009-06-26 |
Schering Corp |
Metodos de tratamiento de cancer con inhibidores del receptor del factor 1 de crecimiento similar a la insulina.
|
US20100143340A1
(en)
|
2006-12-13 |
2010-06-10 |
Schering Corporation |
Methods and compositions for treating cancer
|
CA2671982C
(fr)
|
2006-12-14 |
2016-01-26 |
Exelixis, Inc. |
Procedes d'utilisation d'inhibiteurs de mek
|
WO2008076143A1
(fr)
|
2006-12-18 |
2008-06-26 |
Osi Pharmaceuticals, Inc. |
Combinaison d'un inhibiteur de l'igfr et d'un agent anticancéreux
|
EP2815750A1
(fr)
|
2006-12-21 |
2014-12-24 |
Vertex Pharmaceuticals Incorporated |
Dérivés de 5-cyano-4-(pyrrolo [2,3b] pyridine-3-yl)-pyrimidine utiles en tant qu'inhibiteurs de kinase de protéine
|
AU2008206476A1
(en)
|
2007-01-12 |
2008-07-24 |
Wyeth |
Tablet-in-tablet compositions
|
US9090693B2
(en)
|
2007-01-25 |
2015-07-28 |
Dana-Farber Cancer Institute |
Use of anti-EGFR antibodies in treatment of EGFR mutant mediated disease
|
EP2124901B1
(fr)
|
2007-02-01 |
2017-07-19 |
Takeda Pharmaceutical Company Limited |
Préparation de comprimé ne provoquant pas de problème de pastillage
|
WO2008121467A2
(fr)
|
2007-02-28 |
2008-10-09 |
Dana-Farber Cancer Institute, Inc. |
Polythérapie pour le traitement du cancer
|
GB0706633D0
(en)
|
2007-04-04 |
2007-05-16 |
Cyclacel Ltd |
Combination
|
EP1978106A1
(fr)
|
2007-04-07 |
2008-10-08 |
Universitätsklinikum Hamburg-Eppendorf |
Amplificateur ayant une protection de sortie, en particulier un amplificateur opérationnel pour une application audio
|
JP5926487B2
(ja)
|
2007-04-13 |
2016-05-25 |
デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド |
ErbB療法に耐性である癌を治療するための方法
|
MX2009011228A
(es)
|
2007-04-19 |
2009-11-02 |
Wellstat Biologics Corp |
Deteccion de niveles elevados de la proteina her-2/neu de celulas cancerosas circulantes no aisladas y tratamiento.
|
WO2008136838A1
(fr)
|
2007-05-04 |
2008-11-13 |
Trustees Of Dartmouth College |
Nouveaux dérivés d'amide de cddo et leurs procédés d'utilisation
|
WO2009005673A1
(fr)
|
2007-06-28 |
2009-01-08 |
Schering Corporation |
Anti-igf1r
|
WO2009036059A2
(fr)
|
2007-09-10 |
2009-03-19 |
Boston Biomedical, Inc. |
Nouveaux inhibiteurs de la voie stat3 et nouveaux inhibiteurs de cellules souches cancéreuses
|
WO2009042613A1
(fr)
|
2007-09-24 |
2009-04-02 |
Tragara Pharmaceuticals, Inc. |
Polythérapie pour le traitement de cancer au moyen d'inhibiteurs de la cox-2 et d'inhibiteurs doubles de l'egfr [erbb1] et de l'her-2 [erbb2]
|
US8022216B2
(en)
*
|
2007-10-17 |
2011-09-20 |
Wyeth Llc |
Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
|
CN101918579A
(zh)
|
2007-10-22 |
2010-12-15 |
先灵公司 |
完全人抗-vegf抗体和使用方法
|
AU2008325219A1
(en)
|
2007-11-05 |
2009-05-14 |
Puretech Ventures |
Methods, kits, and compositions for administering pharmaceutical compounds
|
CN101185633A
(zh)
|
2007-12-14 |
2008-05-28 |
山东蓝金生物工程有限公司 |
一种治疗实体肿瘤的尼拉替尼缓释植入剂
|
EP2247757A2
(fr)
|
2007-12-18 |
2010-11-10 |
Schering Corporation |
Biomarqueurs de sensibilité à une thérapie anti-igf1r
|
US20100297118A1
(en)
|
2007-12-27 |
2010-11-25 |
Macdougall John |
Therapeutic Cancer Treatments
|
US20090203709A1
(en)
|
2008-02-07 |
2009-08-13 |
Abbott Laboratories |
Pharmaceutical Dosage Form For Oral Administration Of Tyrosine Kinase Inhibitor
|
WO2009105234A2
(fr)
|
2008-02-19 |
2009-08-27 |
Combinatorx, Incorporated |
Procédés et compositions pour le traitement de troubles associés à des défauts du gène ou de la protéine du régulateur de la conductance transmembranaire d'une fibrose kystique
|
CA2923248A1
(fr)
|
2008-02-25 |
2009-09-03 |
Nestec S.A. |
Methodes de detection de recepteurs tronques
|
WO2009111073A2
(fr)
|
2008-03-06 |
2009-09-11 |
Odyssey Thera, Inc. |
Dosages haute densité et haut rendement permettant d’identifier les voies de régulation lipidique et nouveaux agents thérapeutiques pour les troubles lipidiques
|
US20110104256A1
(en)
|
2008-03-25 |
2011-05-05 |
Yaolin Wang |
Methods for treating or preventing colorectal cancer
|
WO2009121031A1
(fr)
|
2008-03-27 |
2009-10-01 |
Vascular Biosciences, Inc. |
Procédé d'identification de nouveaux candidats thérapeutiques via l'analyse d'expression génique dans les maladies d'origine vasculaire
|
US20090246198A1
(en)
|
2008-03-31 |
2009-10-01 |
Takeda Pharmaceutical Company Limited |
Mapk/erk kinase inhibitors and methods of use thereof
|
WO2009126662A1
(fr)
|
2008-04-08 |
2009-10-15 |
Syndax Pharmaceuticals, Inc. |
Administration d'un inhibiteur de hdac, d'un inhibiteur de her-2, et d'un modulateur du récepteur de l'œstrogène sélectif
|
HUE041221T2
(hu)
|
2008-04-18 |
2019-05-28 |
Reata Pharmaceuticals Inc |
Antioxidáns gyulladás modulátorok: a C-17 atomon amino- és más módosításokkal rendelkezõ oleanolsav-származékok
|
BRPI0911105B1
(pt)
|
2008-04-18 |
2022-11-08 |
Reata Pharmaceuticals, Inc |
Compostos contendo um farmacóforo anti-inflamatório, composição farmacêutica, bem como seus usos
|
WO2009146216A2
(fr)
|
2008-04-18 |
2009-12-03 |
Reata Pharmaceuticals. Inc. |
Modulateurs d’inflammation antioxydant : nouveaux dérivés d’acide oléanolique
|
JP5588966B2
(ja)
|
2008-04-18 |
2014-09-10 |
リアタ ファーマシューティカルズ インコーポレイテッド |
抗酸化炎症モジュレーター:c−17同族体化オレアノール酸誘導体
|
BRPI0911208B1
(pt)
|
2008-04-18 |
2021-05-25 |
Reata Pharmaceuticals, Inc |
Compostos moduladores inflamatórios antioxidantes, seu uso, e composição farmacêutica
|
WO2009137378A2
(fr)
|
2008-05-05 |
2009-11-12 |
Schering Corporation |
Administration séquentielle d’agents de chimiothérapie pour le traitement du cancer
|
WO2009151910A2
(fr)
|
2008-05-25 |
2009-12-17 |
Wyeth |
Produit de combinaison d'un inhibiteur de tyrosine kinase de récepteur et d'un inhibiteur d'acide gras synthase pour le traitement du cancer
|
DK2656844T3
(en)
|
2008-06-17 |
2015-03-02 |
Wyeth Llc |
ANTINEOPLASTIC COMBINATIONS CONTAINING HKI-272 AND VINORELBINE
|
EP2309860B1
(fr)
|
2008-07-22 |
2014-01-08 |
Trustees of Dartmouth College |
Cyanoénones monocycliques et leurs procédés d'utilisation
|
CN105963313A
(zh)
|
2008-08-04 |
2016-09-28 |
惠氏有限责任公司 |
4-苯胺基-3-氰基喹啉和卡培他滨的抗肿瘤组合
|
US20100069340A1
(en)
|
2008-09-11 |
2010-03-18 |
Wyeth |
Pharmaceutical compositions of an src kinase inhibitor and an aromatase inhibitor
|
CN106153918A
(zh)
|
2008-10-14 |
2016-11-23 |
卡里斯Mpi公司 |
描绘肿瘤类型生物标志模式和特征集的基因靶和基因表达的蛋白靶
|
WO2010048477A2
(fr)
|
2008-10-24 |
2010-04-29 |
Wyeth Llc |
Procede ameliore de preparation de produits couples a partir de 4-amino-3-cyanoquinoleines utilisant des intermediaires stabilises
|
CN102223886A
(zh)
|
2008-11-07 |
2011-10-19 |
安龙制药公司 |
Erbb-3(her3)选择性组合疗法
|
WO2010085845A1
(fr)
|
2009-01-28 |
2010-08-05 |
The University Of Queensland |
Diagnostic du cancer et/ou thérapie contre celui-ci
|
TW201032796A
(en)
|
2009-02-04 |
2010-09-16 |
Bipar Sciences Inc |
Treatment of lung cancer with a PARP inhibitor in combination with a growth factor inhibitor
|
WO2010098627A2
(fr)
|
2009-02-27 |
2010-09-02 |
한올바이오파마주식회사 |
Préparation pharmaceutique
|
MX2011009034A
(es)
|
2009-03-11 |
2011-09-22 |
Auckland Uniservices Ltd |
Formas de profarmaco de inhibidores de cinasa y su uso en la terapia.
|
AU2010234968B2
(en)
|
2009-04-06 |
2015-05-14 |
Wyeth Llc |
Treatment regimen utilizing neratinib for breast cancer
|
AR076053A1
(es)
|
2009-04-14 |
2011-05-18 |
Schering Corp |
Derivados de pirazolo[1,5-a]pirimidina como inhibidores de mtor
|
WO2010124009A2
(fr)
|
2009-04-21 |
2010-10-28 |
Schering Corporation |
Anticorps anti-vegf entièrement humains et méthodes d'utilisation de ceux-ci
|
CN102482277B
(zh)
|
2009-05-05 |
2017-09-19 |
达纳-法伯癌症研究所有限公司 |
表皮生长因子受体抑制剂及治疗障碍的方法
|
AU2010266342A1
(en)
|
2009-07-02 |
2012-01-19 |
Wyeth Llc |
3-cyanoquinoline tablet formulations and uses thereof
|
US20120135952A1
(en)
|
2009-07-17 |
2012-05-31 |
Hanall Biopharma Co., Ltd. |
Butyric acid salt of n,n-dimethyl imidocarbon imidic diamide, method of preparing same, and pharmaceutical compositions and combinations containing same
|
WO2011008053A2
(fr)
|
2009-07-17 |
2011-01-20 |
한올바이오파마주식회사 |
Propionate de n,n-diméthyl diamide imidocarbonimidique, son procédé de préparation ainsi que compositions et combinaisons pharmaceutiques le contenant
|
WO2011025267A2
(fr)
|
2009-08-25 |
2011-03-03 |
한올바이오파마주식회사 |
Méthanesulfonate de metformine, procédé de préparation correspondant, composition pharmaceutique le comprenant et formulation combinée le comprenant
|
KR101190953B1
(ko)
|
2009-08-25 |
2012-10-12 |
한올바이오파마주식회사 |
메트포르민 타우린염, 그의 제조방법, 그를 포함하는 약학 조성물 및 그를 포함하는 복합제제
|
KR101211227B1
(ko)
|
2009-08-25 |
2012-12-11 |
한올바이오파마주식회사 |
메트포르민 아스코르브산염, 그의 제조방법, 그를 포함하는 약학 조성물 및 그를 포함하는 복합제제
|
US20110055838A1
(en)
|
2009-08-28 |
2011-03-03 |
Moyes William A |
Optimized thread scheduling via hardware performance monitoring
|
WO2011038467A1
(fr)
|
2009-10-01 |
2011-04-07 |
Csl Limited |
Procédé de traitement de la leucémie à chromosome philadelphie positive
|
CN106074445B
(zh)
|
2009-11-09 |
2018-12-21 |
惠氏有限责任公司 |
包衣药物球状体及其制备消除或减少病症的药物的用途
|
RS59599B2
(sr)
|
2009-11-09 |
2023-03-31 |
Wyeth Llc |
Formulacije tableta neratinib maleata
|
HUE035605T2
(en)
|
2009-11-13 |
2018-05-28 |
Daiichi Sankyo Europe Gmbh |
Materials and Methods for the Treatment or Prevention of HER-3-Related Diseases
|
JP2013512882A
(ja)
|
2009-12-07 |
2013-04-18 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
トリプルネガティブ乳癌の治療に使用するbibw2992
|
EP2510121A1
(fr)
|
2009-12-11 |
2012-10-17 |
Wyeth LLC |
Biomarqueurs de la voie de la phosphatidylinotisol-3-kinase
|
CA2787048C
(fr)
|
2010-01-13 |
2021-06-22 |
Wyeth Llc |
Point de decoupage dans l'expression de la proteine pten qui identifie avec precision les tumeurs et qui permet de predire la reponse medicamenteuse a un inhibiteur de pan-erbb
|